Humana 1999 Annual Report Download - page 28

Download and view the complete annual report

Please find page 28 of the 1999 Humana annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 30

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30

HU M A N A IN C .
Q U A RT E R LY FINANCIAL INFORMATION (UNAUDITED)
A summary of the Company’s quarterly unaudited results of operations for the years ended December 31, 1999 and 1998 follows:
(In millions, except per share results) 1999
First (a) Second Third Fourth (b)
Revenues $ 2,477 $ 2,505 $ 2,557 $ 2,574
(Loss) income before income taxes (25) 44 34 (457)
Net (loss) income (16) 28 22 (416)
(Loss) earnings per common share (0.10) 0.17 0.13 (2.48)
(Loss) earnings per common share —
assuming dilution (0.10) 0.17 0.13 (2.48)
(In millions, except per share results) 1998
First Second Third (c) Fourth
Revenues $ 2,402 $ 2,446 $ 2,464 $ 2,469
Income (loss) before income taxes 79 82 (47) 89
Net income (loss) 50 52 (30) 57
Earnings (loss) per common share 0.30 0.31 (0.18) 0.34
Earnings (loss) per common share —
assuming dilution 0.30 0.31 (0.18) 0.34
(a) Includes expenses of $90 million pretax ($58 million af ter tax, or $0. 34 per diluted share) primarily related to premium defi cien cy and med ical re s e r ve st re n g t h e n i n g .
(b) Includes expenses of $495 million pret ax ($44 1 after tax , or $2.63 per diluted share) primarily related to goodwill wri te-down, losses on no n-core asset sales and professional liability
(c) re s e rve stre n g t h e n i n g .
(c) Includes expenses of $132 million ($ 84 million af ter ta x, or $0.50 per diluted share) primarily related to the costs of cert ain marke t e xits and product discontinuances, asset wri te-downs,
(c) p remium deficiency and a one-time non- of fi cer employee incentive.
HU M A N A IN C .
BOARD COMMITTEES
5352
K. Frank Austen, M.D.
Theodore B. Bayles Professor of
Medicine, Harvard Medical School
and the Brigham and Women’s
Hospital
Michael E. Gellert
General Partner, Windcrest Partners,
private investment partnership
John R. Hall
Retired Chairman of the Board
and Chief Executive Officer,
Ashland Inc.
David A. Jones
Chairman of the Board, Humana Inc.
David A. Jones, Jr.
Vice Chairman, Humana Inc.
Chairman and Managing Director,
Chrysalis Ventures, L.L.C.
venture capital firm
Irwin Lerner
Retired Chairman of the Board
and of the Executive Committee,
Hoffmann-LaRoche Inc.
Michael B. McCallister
President and Chief Executive Officer,
Humana Inc.
W.Ann Reynolds, Ph.D.
President, University of Alabama at
Birmingham
Executive Committee
David A. Jones, Chairman
Michael E. Gellert
David A. Jones, Jr.
Michael B. McCallister
Medical Affairs Committee
K. Frank Austen, M.D., Chairman
Irwin Lerner
W. Ann Reynolds, Ph.D.
Audit Committee
Michael E. Gellert, Chairman
K. Frank Austen, M.D.
John R. Hall
Irwin Lerner
Nominating and Corporate
Governance Committee
John R. Hall, Chairman
David A. Jones, Jr.
W.Ann Reynolds, Ph.D.
Investment Committee
W. Ann Reynolds, Ph.D., Chairwoman
K. Frank Austen, M.D.
Michael E. Gellert
David A. Jones, Jr.
Organization and Compensation
Committee
Irwin Lerner, Chairman
K. Frank Austen, M.D.
Michael E. Gellert
John R. Hall
HU M A N A IN C ./
BOARD OF DIRECTORS